Ann Hepatobiliary Pancreat Surg.  2022 Feb;26(1):40-46. 10.14701/ahbps.21-094.

Do changes in inflammatory markers predict hepatocellular carcinoma recurrence and survival after liver transplantation?

Affiliations
  • 1Division of Hepato Pancreatic Biliary Surgery and Liver Transplant Unit, Department of General Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
  • 2Department of Internal Medicine and Hepatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
  • 3Department of Internal Medicine and Statistics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Abstract

Backgrounds/Aims
The role of inf lammation in malignant cell proliferation has been well described. High values of platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) as markers of systemic inf lammation have shown associations with unfavorable long-term outcomes. The purpose of this study was to determine values of NLR and PLR evaluated prior to and after surgery and their associations with mortality and recurrence rates of liver transplant patients with hepatocellular carcinoma (HCC).
Methods
A total of 105 patients with HCC who underwent orthotopic liver transplantation (OLT) were retrospectively reviewed. NLR and PLR values were obtained from complete blood counts prior to and after surgery. Overall survival (OS) and recurrence-free survival (RFS) in relation with delta NLR and PLR were estimated.
Results
Serum alpha-fetoprotein levels > 100 ng/mL (p = 0.014) and lymphovascular emboli in the specimen (p = 0.048) were identified to be significant predictors of RFS. Child-Pugh score (p = 0.016) was found to be an independent factor associated with poorer OS. An increasing delta PLR was associated with worse RFS, although it showed no significant association with OS.
Conclusions
The analysis of PLR as a continuous variable may predict recurrence outcomes in patients undergoing OLT for HCC. It is more representative than isolated values.

Keyword

Transplantation; Liver neoplasms; Recurrence; Neutrophils; Platelets

Figure

  • Fig. 1 Selection of patients included in this study. OLT, orthotopic liver transplantation.

  • Fig. 2 The Kaplan–Meier curve showing recurrence-free survival (RFS) of orthotopic liver transplantation (OLT) patients.

  • Fig. 3 The Kaplan–Meier curve showing overall survival of orthotopic liver transplantation patients.

  • Fig. 4 The Kaplan–Meier curve showing recurrence-free survival (RFS) according to delta platelet-lymphocyte ratio (PLR) trends.


Reference

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. DOI: 10.3322/caac.21492. PMID: 30207593.
Article
2. International Agency for Research on Cancer (IARC). Fact sheets by population-Globocan-IARC [Internet]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Lyon: IARC;2020. cited 2016 Dec 18.
3. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. 2018; AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 67:358–380. DOI: 10.1002/hep.29086. PMID: 28130846.
Article
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. 1996; Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:693–699. DOI: 10.1056/NEJM199603143341104. PMID: 8594428.
Article
5. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. 2001; Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 33:1394–1403. DOI: 10.1053/jhep.2001.24563. PMID: 11391528.
Article
6. Forner A, Reig M, Bruix J. 2018; Hepatocellular carcinoma. Lancet. 391:1301–1314. DOI: 10.1016/S0140-6736(18)30010-2. PMID: 29307467.
Article
7. Tandon P, Garcia-Tsao G. 2009; Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 29:502–510. DOI: 10.1111/j.1478-3231.2008.01957.x. PMID: 19141028. PMCID: PMC2711257.
Article
8. Balkwill F, Mantovani A. 2001; Inflammation and cancer: back to Virchow? Lancet. 357:539–545. DOI: 10.1016/S0140-6736(00)04046-0. PMID: 11229684.
Article
9. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. 1997; The codependence of angiogenesis and chronic inflammation. FASEB J. 11:457–465. DOI: 10.1096/fasebj.11.6.9194526. PMID: 9194526.
Article
10. Wang D, Bai N, Hu X, OuYang XW, Yao L, Tao Y, et al. 2019; Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 7:e7132. DOI: 10.7717/peerj.7132. PMID: 31632844. PMCID: PMC6796955.
Article
11. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. 2014; Prognostic value of PLR in various cancers: a meta-analysis. PLoS One. 9:e101119. DOI: 10.1371/journal.pone.0101119. PMID: 24968121. PMCID: PMC4072728.
Article
12. Zheng J, Cai J, Li H, Zeng K, He L, Fu H, et al. 2017; Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem. 44:967–981. DOI: 10.1159/000485396. PMID: 29179180.
Article
13. Al Lawati Y, Cools-Lartigue J, Ramirez-GarciaLuna JL, Molina-Franjola JC, Pham D, Skothos E, et al. 2020; Dynamic alteration of neutrophil-to-lymphocyte ratio over treatment trajectory is associated with survival in esophageal adenocarcinoma. Ann Surg Oncol. 27:4413–4419. DOI: 10.1245/s10434-020-08521-7. PMID: 32363513.
Article
14. Celik N, Kelly B, Soltys K, Squires JE, Vockley J, Shellmer DA, et al. 2019; Technique and outcome of domino liver transplantation from patients with maple syrup urine disease: expanding the donor pool for live donor liver transplantation. Clin Transplant. 33:e13721. DOI: 10.1111/ctr.13721. PMID: 31556146.
Article
15. Tsochatzis EA, Germani G, Burroughs AK. 2010; Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol. 37:89–93. DOI: 10.1053/j.seminoncol.2010.03.007. PMID: 20494700.
Article
16. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. 2013; The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 88:218–230. DOI: 10.1016/j.critrevonc.2013.03.010. PMID: 23602134.
Article
17. Zhan H, Ma JY, Jian QC. 2018; Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: a meta-analysis. Clin Chim Acta. 484:136–140. DOI: 10.1016/j.cca.2018.05.055. PMID: 29856976.
Article
18. Choi N, Kim JH, Chie EK, Gim J, Kang HC. 2019; A meta-analysis of the impact of neutrophil-to-lymphocyte ratio on treatment outcomes after radiotherapy for solid tumors. Medicine (Baltimore). 98:e15369. DOI: 10.1097/MD.0000000000015369. PMID: 31045780. PMCID: PMC6504242.
Article
19. Yu Y, Wang H, Yan A, Wang H, Li X, Liu J, et al. 2018; Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis. BMC Cancer. 18:383. DOI: 10.1186/s12885-018-4230-z. PMID: 29618336. PMCID: PMC5885417.
Article
20. Suh J, Jung JH, Jeong CW, Kwak C, Kim HH, Ku JH. 2019; Clinical significance of pre-treated neutrophil-lymphocyte ratio in the management of urothelial carcinoma: a systemic review and meta-analysis. Front Oncol. 9:1365. DOI: 10.3389/fonc.2019.01365. PMID: 31921631. PMCID: PMC6927426.
Article
21. Wang Z, Zhan P, Lv Y, Shen K, Wei Y, Liu H, et al. 2019; Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. Transl Lung Cancer Res. 8:214–226. DOI: 10.21037/tlcr.2019.06.10. PMID: 31367535. PMCID: PMC6626865.
Article
22. Yuan D, Zhu K, Li K, Yan R, Jia Y, Dang C. 2014; The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction. J Surg Oncol. 110:333–340. DOI: 10.1002/jso.23651. PMID: 24889121.
Article
23. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. 2012; Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 143:986–994.e3. quiz e14–e15. DOI: 10.1053/j.gastro.2012.05.052. PMID: 22750200.
Article
24. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, et al. 2018; Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 154:128–139. DOI: 10.1053/j.gastro.2017.09.025. PMID: 28989060.
Article
25. Mansour A, Watson W, Shayani V, Pickleman J. 1997; Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery. 122:730–735. discussion 735–736. DOI: 10.1016/S0039-6060(97)90080-5. PMID: 9347849.
Article
26. Garrison RN, Cryer HM, Howard DA, Polk HC Jr. 1984; Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg. 199:648–655. DOI: 10.1097/00000658-198406000-00003. PMID: 6732310. PMCID: PMC1353440.
Article
27. Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, et al. 2014; Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. J Surg Res. 192:402–408. DOI: 10.1016/j.jss.2014.05.078. PMID: 24998425.
Article
28. Liu J, Lin PC, Zhou BP. 2015; Inflammation fuels tumor progress and metastasis. Curr Pharm Des. 21:3032–3040. DOI: 10.2174/1381612821666150514105741. PMID: 26004407. PMCID: PMC5644345.
Article
Full Text Links
  • AHBPS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr